title: Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.
abstract: Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy.
authors.affiliation: Institute of Neurology, Catholic University, Largo Gemelli 8, 00168 Rome, Italy.
authors.forename: Marcella
authors.initials: M
authors.lastname: Caggiula
authors.forename: Anna Paola
authors.initials: AP
authors.lastname: Batocchi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Frisullo
authors.forename: Francesco
authors.initials: F
authors.lastname: Angelucci
authors.forename: Agata Katia
authors.initials: AK
authors.lastname: Patanella
authors.forename: Cristina
authors.initials: C
authors.lastname: Sancricca
authors.forename: Viviana
authors.initials: V
authors.lastname: Nociti
authors.forename: Pietro Attilio
authors.initials: PA
authors.lastname: Tonali
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Mirabella
mesh_terms: D000328:Adult; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000097:blood* / Q000188:drug therapy; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000188:drug therapy; D009414:Nerve Growth Factors / Q000096:biosynthesis*; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D009414:Nerve Growth Factors; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a